Value and toxicity of therapy for idiopathic nephrotic syndrome in the child.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001796:Blood Protein Disorders / Q000209:etiology; D002648:Child; D002740:Chlorothiazide / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004039:Diet, Sodium-Restricted; D004044:Dietary Proteins / Q000627:therapeutic use; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006977:Hypertension, Renal / Q000188:drug therapy; D008750:Methyldopa / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D010952:Plasma Substitutes / Q000627:therapeutic use; D012146:Rest; D012709:Serum Albumin / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004044:Dietary Proteins; D005938:Glucocorticoids; D010952:Plasma Substitutes; D012709:Serum Albumin; D006852:Hydrochlorothiazide; D013148:Spironolactone; D008750:Methyldopa; D002740:Chlorothiazide; D005665:Furosemide; D003520:Cyclophosphamide; D004976:Ethacrynic Acid